Clinical Trial Update: Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating relatlimab with nivolumab and 5-azacytidine for acute myeloid leukemia (AML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• 5-Azacytidine (5-azacytidine)
• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN